Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label trial (G-alfalfa trial)
Introduction Compared with the guideline-recommended use of low-molecular weight heparin (LMWH) for 28 days to prevent venous thromboembolism (VTE) after cytoreductive surgery, oral rivaroxaban avoids the pain and inconvenience of daily injections and reduces medical expenses. The proposed randomise...
Saved in:
Main Authors: | Hong Zhou, Fei He, Ting Wei, Shuyi Wu, Jinhua Zhang, Huan Yi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/12/e092164.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Direct oral anticoagulants (DOACs) for postoperative venous thromboembolism prophylaxis in patients with gynecologic malignancies: A quality mini-review
by: Peter W. Ketch, et al.
Published: (2024-12-01) -
Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism
in Saudi Arabia
by: Abdulaali R. Almutairi PhD, et al.
Published: (2025-02-01) -
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01) -
Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol
by: Shigeki Takai, et al.
Published: (2019-11-01) -
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
by: Maarten J Postma, et al.
Published: (2020-11-01)